Aarti Industries Ltd. announces a new order win

Phase I’s total capitalized cost is not reported in the commissioning announcement. The filing confirms commissioning of Calcium Chloride, PEDA and part of the Multipurpose Plant at Jhagadia on 7 September 2026, but gives no project-cost or Phase-I capitalization figure.^[1]

Asset-turnover impact

The latest reported consolidated base before the commissioning comprises total assets of Rs 13,300.2 Crores, fixed assets of Rs 8,391.1 Crores and capital work in progress of Rs 2,029.5 Crores. Consolidated asset turnover was 0.74x in Q1 FY27.^{[2] [3] [4] [5]}

The effect depends on whether Phase I is:

• A transfer from existing CWIP to property, plant and equipment: total assets would not rise merely because of the accounting reclassification. Asset turnover would then depend mainly on how quickly the commissioned units generate revenue.
• Incremental capex not already included in the reported asset base: turnover would initially decline mechanically if revenue does not rise at the same pace. If `C` is the incremental capitalized cost in Rs Crores, the indicative turnover becomes:

`New asset turnover = 0.74 × 13,300.2 / (13,300.2 + C)`

This is only a mechanical sensitivity, not a reported company calculation. Management stated that customer approvals, commercial qualification and production ramp-up would follow commissioning, with progressive commercialization expected during the fiscal year.^{[1] [1]} Therefore, the likely near-term pattern is asset-base expansion ahead of full revenue contribution, followed by improvement in turnover only as utilization and sales scale.

Depreciation implications

Existing consolidated depreciation was 5.2% of revenue in Q1 FY27 and 5.4% on a TTM basis; TTM depreciation-to-revenue had declined from 6.1% in Q2 FY26 to 5.4% in Q1 FY27.^{[6] [7]}

The Phase-I addition should create an incremental depreciation charge once the assets are available for use. For FY27, that would ordinarily be a partial-year charge from the commissioning/available-for-use date, rather than a full-year charge. However, the incremental amount and exact schedule cannot be calculated because the company has not reported the Phase-I cost, component-wise useful lives, residual values, depreciation method or the precise accounting transfer from CWIP to operating fixed assets.

Analytical conclusion: the immediate accounting impact is likely to be a higher depreciation run-rate and, if Phase-I cost is incremental to the existing asset base, a temporary dilution in asset turnover. The economic outcome depends on whether commercial ramp-up occurs quickly enough to offset the larger depreciating asset base.

Zone IV is expected to become a meaningful specialty-chemicals growth contributor over the next two to three years, but management has not quantified its contribution as a percentage of segment revenue. The ramp is expected to be phased as capacities stabilise; revenue accrual was indicated from Q2 FY27. ^{[8] [9]}

The products targeted for Zone IV—primarily niche agrochemical and pharmaceutical applications—are expected to generate EBITDA margins of approximately 25–30%. ^[10] This is materially above Aarti Industries’ recent consolidated margin benchmarks:

• Q1 FY27 consolidated EBITDA margin: 16.1%, making the Zone IV target 8.9–13.9 percentage points higher. ^[11]
• Q1 FY27 TTM consolidated EBITDA margin: 14.9%, making the target 10.1–15.1 percentage points higher. ^[12]

The important caveat is that Aarti has not separately disclosed a historical EBITDA average for the specialty-chemicals segment, so the comparison against a segment-specific historical average cannot be made directly. The company-wide margin comparison is only a proxy. If achieved, the 25–30% target would nevertheless represent a clear mix-upgrade versus the company’s recent consolidated profitability, although the eventual group impact will depend on Zone IV’s revenue scale and commissioning pace.

The disclosures do not state a numeric total capacity for the full Zone IV project, nor do they disclose the remaining Zone IV-specific capex required to reach that capacity. The project is described as a multi-block platform comprising Calcium Chloride, PEDA, part of the Multipurpose Plant, and additional chemistry blocks, but no aggregate tonnes-per-annum or equivalent capacity is provided ^{[1] [13]}.

Phase timeline

• Phase I: Commissioned at Jhagadia on 7 September 2026, covering Calcium Chloride, PEDA and part of the MPP ^[1].
• Subsequent phases: Zone IV and the related chlorotoluene value-chain projects were expected to be commissioned progressively over the next three quarters, implying phasing through Q2-Q4 FY27 from the Q1 FY27 update ^[14].
• MPP ramp-up: Products from the PEDA and MPP platforms were expected to scale over the following two quarters, with new MPP capacity coming on stream in Q2 FY27, subject to customer qualification ^[15].
• Full commercialisation: Management said it remained on track to progressively commercialise all manufacturing blocks within Zone IV during FY27, but this refers to commissioning/commercialisation rather than a disclosed date for reaching steady-state or 100% utilisation ^[1].

Capex position

• Aarti’s total FY27 capex programme was guided at Rs 700-800 Crores ^[14].
• That figure covers the company’s broader growth programme; the amount already spent on Zone IV, the balance remaining, and the Zone IV share of the Rs 700-800 Crores have not been separately disclosed.
• Therefore, the supported conclusion is: full Zone IV commercialisation is targeted progressively by the end of FY27, but the remaining project outlay and total operating capacity cannot be quantified from the reported disclosures.